文献速递其他结缔组织病

全身型幼年特发性关节炎中新发现的高致死性肺病

Emergent high fatality lung disease in systemic juvenile arthritis.
PubMed 文献 · Ann Rheum Dis · 2019-09-27

这项多中心回顾性研究分析了61例全身型幼年特发性关节炎(sJIA)患者中新发现的实质性肺病(LD)。LD具有独特临床特征,包括杵状指、对托珠单抗的过敏反应及血清铁蛋白升高或淋巴细胞减少,5年生存率仅42%。IL-1和IL-6抑制剂暴露可能与LD相关,且不依赖于sJIA严重程度。

要点

  • sJIA相关LD表现为杵状指、托珠单抗过敏反应及铁蛋白升高或淋巴细胞减少。
  • 胸部CT以间隔增厚为主,病理多见肺泡蛋白沉积症/内源性脂性肺炎变异型。
  • 5年生存率42%,21三体及低龄起病增加LD风险,抑制剂暴露可能促进LD。

核心结论

  • sJIA中一种罕见的致死性肺病由独特临床特征群定义,病理为PAP/ELP变异型,提示巨噬细胞功能障碍。
  • IL-1和IL-6抑制剂暴露可能在小部分治疗患者中促进LD,且独立于sJIA严重程度。

研究设计与样本

  • 多中心回顾性研究,纳入61例sJIA患者,采用医生报告的临床信息及影像学、病理学和遗传学集中分析。

主要发现

  • LD相关特征包括急性红斑性杵状指和对IL-6抑制剂托珠单抗的高频过敏反应。
  • 血清铁蛋白升高和/或显著淋巴细胞减少先于LD检测。
  • 最常见胸部CT模式为间隔增厚,累及多肺叶外周±磨玻璃影。
  • 主要病理(36例中23例)为肺泡蛋白沉积症和/或内源性脂性肺炎(PAP/ELP),伴区域受累及血管改变等非典型特征。
  • 5年生存率为42%;21三体和低龄sJIA起病增加LD风险。

关键数值与推荐

  • 全外显子测序(61例中20例)未发现新的单基因缺陷或可能致病的PAP相关或MAS相关突变。
  • 61例中46例有IL-1和IL-6抑制剂暴露,暴露与多个LD特征相关。
  • 药物暴露者中sJIA起病时MAS增加,但与LD特征无关。

临床怎么用

  • 对sJIA患者需警惕新发肺病,尤其出现杵状指、托珠单抗过敏反应、铁蛋白升高或淋巴细胞减少时。
  • 胸部CT间隔增厚及病理PAP/ELP变异型应提示LD可能。
  • 使用IL-1或IL-6抑制剂时需监测肺部表现,目前尚无明确防治策略。

局限性

  • 回顾性研究设计,样本量较小(61例),可能存在选择偏倚。
  • 全外显子测序仅在部分病例(20/61)中进行,遗传学证据有限。
  • 抑制剂暴露与LD的因果关系无法从本研究中确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the characteristics and risk factors of a novel parenchymal lung disease (LD), increasingly detected in systemic juvenile idiopathic arthritis (sJIA). METHODS: In a multicentre retrospective study, 61 cases were investigated using physician-reported clinical information and centralised analyses of radiological, pathological and genetic data. RESULTS: LD was associated with distinctive features, including acute erythematous clubbing and a high frequency of anaphylactic reactions to the interleukin (IL)-6 inhibitor, tocilizumab. Serum ferritin elevation and/or significant lymphopaenia preceded LD detection. The most prevalent chest CT pattern was septal thickening, involving the periphery of multiple lobes ± ground-glass opacities. The predominant pathology (23 of 36) was pulmonary alveolar proteinosis and/or endogenous lipoid pneumonia (PAP/ELP), with atypical features including regional involvement and concomitant vascular changes. Apparent severe delayed drug hypersensitivity occurred in some cases. The 5-year survival was 42%. Whole exome sequencing (20 of 61) did not identify a novel monogenic defect or likely causal PAP-related or macrophage activation syndrome (MAS)-related mutations. Trisomy 21 and young sJIA onset increased LD risk. Exposure to IL-1 and IL-6 inhibitors (46 of 61) was associated with multiple LD features. By several indicators, severity of sJIA was comparable in drug-exposed subjects and published sJIA cohorts. MAS at sJIA onset was increased in the drug-exposed, but was not associated with LD features. CONCLUSIONS: A rare, life-threatening lung disease in sJIA is defined by a constellation of unusual clinical characteristics. The pathology, a PAP/ELP variant, suggests macrophage dysfunction. Inhibitor exposure may promote LD, independent of sJIA severity, in a small subset of treated patients. Treatment/prevention strategies are needed.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019. PMID: 31562126. doi:10.1136/annrheumdis-2019-216040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。